Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH Rare Diseases Project Could Have Broad Effect On Personalized Medicine

Executive Summary

In a high profile effort to speed along personalized medicine, the heads of the National Institutes of Health and FDA are pointing out the possible commercial applications of seemingly small steps, such as the potential for an NIH initiative to accelerate development of therapies for rare diseases to advance personalized medicine in more common illnesses

You may also be interested in...



Appropriations Negotiators Allow NIH Translational Science Center Launch

NIH receives more than $500 million to finance the National Center for Advancing Translational Science, created in the consolidated fiscal 2012 appropriations bill. Members of Congress cautioned that NCATS’ work to speed up drug development should not inhibit private efforts in the same arena.

Appropriations Negotiators Allow NIH Translational Science Center Launch

NIH receives more than $500 million to finance the National Center for Advancing Translational Science, created in the consolidated fiscal 2012 appropriations bill. Members of Congress cautioned that NCATS’ work to speed up drug development should not inhibit private efforts in the same arena.

NIH Translational Science Center Becomes A (Cash-limited) Reality

NIH receives more than one-half billion dollars to finance activities of the National Center for Advancing Translational Science, which came into being when President Obama signed a consolidated fiscal 2012 appropriations bill Dec. 23. House and Senate members who negotiated the final bill cautioned that NCATS’ efforts to find ways to speed up drug development should not inhibit private efforts in the same arena.

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel